Abstract
RASopathies are a group of syndromes caused by germline mutations of the RAS/MAPK pathway. They include Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, and Noonan syndrome with multiple lentigines, which share many characteristic features including cardiac abnormalities. Here, we retrospectively reviewed the clinical manifestations and evaluated the genotype–phenotype associations with special focus on cardiac lesions of the patients with RASopathies. Cardiac symptoms were the most common initial presentation (27 %), except for admission to neonatal intensive care. Although there was a significant gap between the first visit to the hospital and the diagnosis of the genetic syndrome (19.9 ± 39.1 months), the age at the clinical diagnosis of the genetic syndrome was significantly lower in patients with CHD than in patients without CHD (47.26 ± 67.42 vs. 86.17 ± 85.66 months, p = 0.005). A wide spectrum of cardiac lesions was detected in 76.1 % (118/155) of included patients. The most common lesion was pulmonary stenosis, followed by atrial septal defect and hypertrophic cardiomyopathy (HCMP). About half of the pulmonary stenosis and HCMP patients progressed during the median follow-up period of 109.9 (range 9.7–315.4) months. Early rapid aggravation of cardiac lesions was linked to poor prognosis. MEK1, KRAS, and SOS1 mutations tend to be highly associated with pulmonary stenosis. Cardiologists may play important roles in early detection and diagnosis of RASopathies as well as associated CHDs. Due to the variety of clinical presentations and their progression of severity, proper management with regular long-term follow-up of these patients is essential.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lee BH, Kim JM, Jin HY, Kim GH, Choi JH, Yoo HW (2011) Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J Pediatr 159:1029–1035
Tidyman WE, Rauen KA (2009) The RASopathies: developmental syndromes of RAS/MAPK pathway dysregulation. Curr Opin Genet Dev 19:230–236
Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B (1999) Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 135:703–706
Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B et al (2002) Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71:389–394
Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T et al (2007) Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet 44:763–771
Gripp KW, Lin AE, Nicholson L, Allen W, Cramer A, Jones KL et al (2007) Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. Am J Med Genet Part A 143A:1472–1480
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL et al (2008) Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 93:4210–4217
Gravino R, Pacileo G (2014) Cardiac imaging in RASopathies/mitogen activated protein kinase syndromes. Cardiogenetics 4:2198
Aoki Y, Niihori T, Inoue S, Matsubara Y (2016) Recent advances in RASopathies. J Hum Genet 61:33–39
Lin AE, Basson CT, Goldmuntz E, Magoulas PL, McDermott DA, McDonald-McGinn DM et al (2008) Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management. Genet Med 10:469–494
Digilioa MC, Marinob B, Sarkozyc A, Versaccib P, Dallapiccolac B (2009) The heart in Ras-MAPK pathway disorders. In: Zenker M (ed) Noonan syndrome and related disorders: a matter of deregulated RAS signaling. Karger, Basel, pp 109–118
Sharland M, Burch M, McKenna WM, Paton MA (1992) A clinical study of Noonan syndrome. Arch Dis Child 67:178–183
Roberts AE, Allanson JE, Tartaglia M, Gelb BD (2013) Noonan syndrome. Lancet 381:333–342
Prendiville TW, Gauvreau K, Tworog-Dube E, Patkin L, Kucherlapati RS, Roberts AE et al (2014) Cardiovascular disease in Noonan syndrome. Arch Dis Child 99:629–634
Gripp KW, Lin AE (2012) Costello syndrome: a RAS/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med 14:285–292
Tartaglia M, Gelb BD, Zenker M (2011) Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 25:161–179
Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF et al (2012) Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J 164:442–448
Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P et al (2007) Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol 100:736–741
Cerrato F, Pacileo G, Limongelli G, Gagliardi MG, Santoro G, Digilio MC et al (2008) A standard echocardiographic and tissue doppler study of morphological and functional findings in children with hypertrophic cardiomyopathy compared to those with left ventricular hypertrophy in the setting of Noonan and LEOPARD syndromes. Cardiol Young 18:575–580
Tartaglia M, Gelb BD (2005) Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genom Hum Genet 6:45–68
Lauriol J, Kontaridis MI (2011) PTPN11-associated mutations in the heart: has LEOPARD changed its RASpots? Trends Cardiovasc Med 21:97–104
Sarkozy A, Conti E, Seripa D, Digilio MC, Grifone N, Tandoi C et al (2003) Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J Medi Genet 40:704–708
Brasil AS, Pereira AC, Wanderley LT, Kim CA, Malaquias AC, Jorge AA et al (2010) PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes. Genetic Test Mol Biomark 14:425–432
Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME et al (2010) Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 126:746–759
Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y (2008) The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29:992–1006
Acknowledgments
This research was supported by the Grant from the National Research Foundation of Korea, Ministry of Education, Science, and Technology (NRF-2016M3A9B4915706) and from the Ministry of Trade, Industry and Energy (Grant No. 10053626).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest or financial disclosure related to this study.
Ethical Standards
All procedures performed in studies involving human participation were in accordance with the ethical standards of the Institutional and/or National Research Committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed Consent
All patients gave informed consent prior to their inclusion in the study.
Rights and permissions
About this article
Cite this article
Jhang, W.K., Choi, JH., Lee, B.H. et al. Cardiac Manifestations and Associations with Gene Mutations in Patients Diagnosed with RASopathies. Pediatr Cardiol 37, 1539–1547 (2016). https://doi.org/10.1007/s00246-016-1468-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-016-1468-6